<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0206257528
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOVONORM 1MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        REPAGLINIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        34.3
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BOEHRINGER INGELHEIM" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BOEHRINGER INGELHEIM
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVO NORDISK
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BX02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NovoNorm&reg; is an oral antidiabetic medicine containing repaglinide which helps your pancreas produce more insulin and thereby lower your blood sugar (glucose).<br /><strong>Type 2 diabetes</strong> is a disease in which your pancreas does not make enough insulin to control the sugar in your blood or where your body does not respond normally to the insulin it produces.<br />NovoNorm&reg; is used to control type 2 diabetes in adults as an add-on to diet and exercise: treatment is usually started if diet, exercise and weight reduction alone have not been able to control (or lower) your blood sugar. NovoNorm&reg; can also be given with metformin or thiazolidinediones, other medicines for diabetes.<br />NovoNorm&reg; has been shown to lower the blood sugar, which helps to prevent complications from your diabetes.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take NovoNorm&reg;:<br />&bull; If you are allergic to repaglinide or any of the other ingredients in this medicine<br />&bull; If you have type 1 diabetes<br />&bull; If the acid level in your blood is raised (diabetic ketoacidosis)<br />&bull; If you have a severe liver disease<br />&bull; If you take gemfibrozil (a medicine used to lower increased fat levels in the blood).</p><p>Take special care with NovoNorm&reg;:<br />&bull; If you have liver problems.<br />NovoNorm&reg; is not recommended in patients with moderate liver disease.<br />NovoNorm&reg; should not be taken if you have a severe liver disease (see Do not take NovoNorm&reg;)<br />&bull; If you have kidney problems.<br />NovoNorm&reg; should be taken with caution<br />&bull; If you are about to have major surgery or you have recently suffered a severe illness or infection. At such times diabetic control may be lost<br />&bull; If you are under 18 or over 75 years of age. NovoNorm&reg; is not recommended. It has not been studied in these age groups.<br />Talk to your doctor if any of the above applies to you. NovoNorm&reg; may not be suitable for you. Your doctor will advise you.</p><p>Children and adolescents<br />Do not take this medicine if you are under 18 years of age.<br />If you get a hypo (low blood sugar) You may get a hypo (short for hypoglycaemia) if your blood sugar gets too low. This may happen:<br />&bull; If you take too much NovoNorm&reg;<br />&bull; If you exercise more than usual<br />&bull; If you take other medicines or suffer from kidney or liver problems (see<br />other sections of 2. What you need to know before you take NovoNorm&reg;).<br />The warning signs of a hypo may come on suddenly and can include: cold<br />sweat; cool pale skin; headache; rapid heart beat; feeling sick; feeling very<br />hungry; temporary changes in vision; drowsiness; unusual tiredness and<br />weakness; nervousness or tremor; feeling anxious; feeling confused; difficulty in<br />concentrating.<br />If your blood sugar is low or you feel a hypo coming on: eat glucose tablets or a sugary snack or drink, then rest. When symptoms of hypoglycaemia<br />have disappeared or when blood sugar levels are stabilised, continue<br />NovoNorm&reg; treatment. Tell people you have diabetes and that if you pass out (become unconscious) due to a hypo, they must turn you on your side and get medical help straight away. They must not give you any food or drink. It could choke you.<br />&bull; If severe hypoglycaemia is not treated, it can cause brain damage<br />(temporary or permanent) and even death &bull; If you have a hypo that makes you<br />pass out, or a lot of hypos, talk to your doctor. The amount of<br />NovoNorm&reg;, food or exercise may need to be adjusted.<br />If your blood sugar gets too high Your blood sugar may get too high<br />(hyperglycaemia). This may happen:<br />&bull; If you take too little NovoNorm&reg;<br />&bull; If you have an infection or a fever<br />&bull; If you eat more than usual<br />&bull; If you exercise less than usual.<br />The warning signs of too high blood<br />sugar appear gradually. They include:<br />increased urination; feeling thirsty; dry skin and dry mouth. Talk to your doctor.</p><p>The amount of NovoNorm&reg;, food or exercise may need to be adjusted.</p><p><strong>Other medicines and NovoNorm&reg;</strong><br />Tell your doctor if you are taking, have recently taken or might take any other<br />medicines.<br />You can take NovoNorm&reg; with metformin or thiazolidinediones, other medicines for diabetes, if your doctor prescribes it.<br />If you take gemfibrozil (used to lower increased fat levels in the blood) you<br />should not take NovoNorm&reg;.<br />Your body&rsquo;s response to NovoNorm&reg; may change if you take other medicines,<br />especially these:<br />&bull; Monoamine oxidase inhibitors (MAOI) (used to treat depression)<br />&bull; Beta blockers (used to treat high blood pressure or heart conditions)<br />&bull; ACE-inhibitors (used to treat heart conditions)<br />&bull; Salicylates (e.g. aspirin)<br />&bull; Octreotide (used to treat cancer)<br />&bull; Nonsteroidal anti-inflammatory drugs (NSAID) (a type of painkillers)<br />&bull; Steroids (anabolic steroids and corticosteroids &ndash; used for anaemia or to treat inflammation)<br />&bull; Oral contraceptives (birth control pills)<br />&bull; Thiazides (diuretics or &lsquo;water pills&rsquo;)<br />&bull; Danazol (used to treat breast cysts and endometriosis)<br />&bull; Thyroid products (used to treat low levels of thyroid hormones)<br />&bull; Sympathomimetics (used to treat asthma)<br />&bull; Clarithromycin, trimethoprim, rifampicin (antibiotic medicines)<br />&bull; Itraconazole, ketoconazole (antifungal medicines)<br />&bull; Gemfibrozil (used to treat high blood fats)<br />&bull; Ciclosporin (used to suppress the immune system)<br />&bull; Deferasirox (used to reduce chronic iron overload)<br />&bull; Clopidogrel (prevents blood clots)</p><p>&bull; Phenytoin, carbamazepine, phenobarbital (used to treat epilepsy)<br />&bull; St. John&rsquo;s wort (herbal medicine).<br /><strong>NovoNorm&reg; with alcohol</strong><br />Alcohol can change the ability of NovoNorm&reg; to reduce the blood sugar.<br />Watch for signs of a hypo.<br /><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are<br />planning to have a baby, ask your doctor for advice before taking this medicine.<br />You should not take NovoNorm&reg; if you are pregnant or are planning to become<br />pregnant. You should not take NovoNorm&reg; if you are breast-feeding.<br /><strong>Driving and using machines</strong><br />Your ability to drive or use a machine may be affected if your blood sugar is low or<br />high. Bear in mind that you could endanger yourself or others. Please ask your doctor whether you can drive a car if you:<br />&bull; Have frequent hypos<br />&bull; Have few or no warning signs of hypos</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.<br />Your doctor will work out your dose.<br />&bull; The normal starting dose is 0.5 mg before each main meal. Swallow the<br />tablets with a glass of water immediately before or up to 30 minutes before each main meal.<br />&bull; The dose may be adjusted by your doctor by up to 4 mg to be taken immediately before or up to 30 minutes before each main meal. The maximum recommended daily dose is 16 mg.<br />Do not take more NovoNorm&reg; than your doctor has recommended.<br />If you take more NovoNorm&reg; than you should<br />If you take too many tablets, your blood sugar may become too low, leading to a<br />hypo. Please see If you get a hypo on what a hypo is and how to treat it.<br />If you forget to take NovoNorm&reg;<br />If you miss a dose, take the next dose as usual - do not double the dose.<br />If you stop taking NovoNorm&reg;<br />Be aware that the desired effect is not achieved if you stop taking NovoNorm&reg;.<br />Your diabetes may get worse. If any change of your treatment is necessary,<br />contact your doctor first.<br />If you have any further questions on the use of NovoNorm&reg;, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, NovoNorm&reg; can cause side effects, although not everybody gets<br />them.</p><p>Hypoglycaemia<br />The most frequent side effect is hypoglycaemia which may affect up to 1 in 10 patients (see If you get a hypo).<br />Hypoglycaemic reactions are generally mild/moderate but may occasionally develop into hypoglycaemic unconsciousness or coma. If this happens, medical assistance is needed immediately.</p><p>Allergy<br />Allergy is very rare (may affect up to 1 in 10,000 patients). Symptoms such as<br />swelling, difficulty in breathing, rapid heartbeat, feeling dizzy and sweating could be signs of anaphylactic reaction.<br />Contact a doctor immediately.</p><p>Other side effects<br />Common (may affect up to 1 in 10 patients)<br />&bull; Stomach pain<br />&bull; Diarrhoea.<br />Rare (may affect up to 1 in 1,000 patients)<br />&bull; Acute coronary syndrome (but it may not be due to the medicine).<br />Very rare (may affect up to 1 in 10,000 patients)<br />&bull; Vomiting<br />&bull; Constipation<br />&bull; Visual disturbances</p><p>&bull; Severe liver problems, abnormal liver function such as increased liver enzymes in your blood.</p><p>Frequency not known<br />&bull; Hypersensitivity (such as rash, itchy skin, redening of the skin, swelling of the skin)<br />&bull; Feeling sick (nausea).<br />If you get any side effects, talk to your doctor or pharmacist. This includes any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep NovoNorm&reg; out of the sight and<br />reach of children.<br />Do not use after the expiry date which is stated on the carton and the blister foil after &lsquo;Expiry&rsquo;. The expiry date refers to the<br />last date of that month.<br />Store in the original package below 30&deg;C to protect from moisture<br />Do not throw away medicines down the drain or in household rubbish. Ask your pharmacist how to throw away medicines<br />you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What NovoNorm&reg; contains<br />The active substance is repaglinide.<br />The other ingredients are microcrystalline cellulose (E460), calcium hydrogen phosphate anhydrous, maize starch, polacrilin potassium, povidone (polyvidone), glycerol 85%, magnesium stearate, meglumine, poloxamer, iron oxide yellow (E172) only in the 1 mg tablets and iron oxide red (E172) only in the 2 mg tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                NovoNorm® tablets are round and convex and engraved with the Novo Nordisk logo (Apis bull). 0.5 mg tablets are white,  1 mg tablets are yellow and 2 mg tablets are peach-coloured. Three blister pack sizes are available. Each pack contains 30, 90 or 120 tablets.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Novo Nordisk A/S<br />Novo All&eacute;<br />DK-2880 Bagsv&aelig;rd, Denmark</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Oct - 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>دواء نوفونورم&reg; يؤخذ عن طريق الفم ويحتوي على مادة الريباجلينايد التي تساعد البنكرياس على إفراز مزيد من الإنسولين ومن ثم يخفض من معدل السكر في الدم الجلوكوز.<br />الداء السكري من النوع الثاني عبارة عن مرض يحدث في حالة عدم إفراز البنكرياس كمية مناسبة من الإنسولين للتحكم في معدل السكر في الدم أو عندما لا يستجيب الجسم بشكل طبيعي للإنسولين المفرز.<br />يستخدم نوفونورم&reg;&nbsp;في التحكم في الداء السكري من النوع الثاني عند البالغين بجانب النظام الغذائي وممارسة الرياضة: عادةً يبدأ العلاج عندما لا يحقق النظام الغذائي والتمارين الرياضية وإنقاص الوزن الأثر المنشود في التحكم أو تقليل مستوى السكر في الدم. ويمكن تناول&nbsp; نوفونورم&reg; أيضًا مع دواء ميتفورمين أو&nbsp;ثيازوليدينديون، أو غيرهما من أدوية علاج السكري.<br />وقد ثبت أن نوفونورم &reg;&nbsp;يخفض من مستوى السكر في الدم، مما يساعد على الوقاية من مضاعفات الداء السكري</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول نوفونورم&reg;<br />&bull; إذا كنت تعاني حساسية ضد مادة الريباجلينايد أو غيرها من المواد المكونة لهذا<br />الدواء<br />&bull; إذا كنت مصابًا بالداء السكري من النوع الأول<br />&bull; إذا كان منسوب الحمض مرتفعًا في دمك الحمض الكيتوني السكري<br />&bull; إذا كنت تعاني مرضًا حادا في الكبد<br />&bull; إذا كنت تتناول دواء جيمفيبروزيل دواء يستخدم لخفض مستويات الدهون الزائدة في الدم.<br />اتخاذ العناية الخاصة مع نوفونورم&reg;<br />&bull; إذا كنت تعاني مشكلات في الكبد فلا ينصح بتناول&nbsp;نوفونورم&reg; مع المرضى الذين يعانون أمراضًا&nbsp; متوسطة في الكبد. وينبغي عدم استخدام&nbsp; نوفونورم&reg; إذا كنت تعاني مرضًا حادًّا في الكبد<br />انظر موانع استخدام نوفونورم&reg;<br />&bull; إذا كنت تعاني مشكلات في الكلى فيجب تناول دواء نوفونورم&reg;&nbsp;بحذر<br />&bull; إذا كنت على وشك إجراء عملية جراحية كبيرة أو كنت تعاني مؤخرًا من مرض شديد أو عدوى. فقد يفقد التحكم في الداء السكري في هذه الحالات.<br />&bull; إذا كان عمرك أقل من 18 أو أكثر من 75 عامًا.&nbsp; فلا ينصح بتناول نوفونورم&reg;&nbsp; فلم تجرَ عليه<br />دراسات أو تجارب في هذه المراحل العمرية.</p><p>استشر طبيبك إذا كان أي مما سبق ينطبق عليك. فقد&nbsp; لا يكون نوفونورم&reg;<br />مناسبًا لك. سيقدم لك الطبيب&nbsp;النصيحة اللازمة في هذا الشأن.<br />الأطفال والمراهقون<br />لا تتناول هذا الدواء إذا كان عمرك أقل من 18 عامًا.<br />إذا أُصبت بحالة نقص سكر الدم انخفاض مستوى السكر في الدم<br />قد تعاني من الهبوط نقص السكر في الدم&nbsp;إذا انخفض معدل السكر في الدم أكثر من اللازم. وقد يحدث هذا في الحالات التالية:<br />&bull; عند تناول كمية كبيرة جداً من نوفونورم&reg;<br />&bull;عند ممارسة الرياضة بشكل أكثر من المعتاد<br />&bull; عند تناول أدوية أخرى أو إذا كنت تعاني مشكلات في الكلى أو الكبد انظر بقية أقسام الجزئية رقم 2 ما تحتاج لمعرفته قبل استعمال نوفونورم&reg;</p><p>&nbsp;</p><p>قد تحدث أعراض نقص سكر الدم بشكل مفاجئ وقد تتضمن ما يلي؛ تعرق بارد؛شحوب البشرة وبرودتها؛<br />صداع؛ سرعة ضربات القلب؛ شعور بالإعياء؛ شعور بالجوع الشديد؛ تغيرات مؤقتة في الرؤية؛ نعاس؛ شعور غير معتاد بالإرهاق والضعف؛ التوتر أو الرعشة؛ شعور بالقلق؛ شعور بالتخبط؛ صعوبة في التركيز.<br />إذا كان سكر الدم منخفضًا لديك أو شعورك ببدء أعراض نقص سكر الدم : فتناول أقراص الجلوكوز أو وجبة خفيفة تحتوي على سكريات أو مشروب، ثم استرح.<br />وعند زوال أعراض نقص سكر الدم أو عند استقرار من &reg; مستويات سكر الدم، استمر في تناول نوفونورم جديد.<br />أخبر من حولك أنك مريض سكر وأنك إذا أصبت بغيبوبة فقدت الوعي&nbsp;نتيجة هبوط مستوى السكر في الدم، يجب أن يضعوك على جانبك ويقدموا لك المساعدة الطبية بشكل فوري. ويجب ألا يعطوك طعاماً أو شراباً. فقد يؤدي هذا إلى اختناقك.<br />&bull; إن لم يعالج نقص سكر الدم الحاد فقد يتسبب في تلف المخ )بشكل مؤقت أو دائم بل وقد يسبب الوفاة<br />&bull; في حالة الإصابة بغيبوبة بسبب نقص سكر الدم أو تكرار الإصابة بنقص سكر الدم، فقد تكون كمية دواء نوفونورم &reg;&nbsp;أو الطعام أو &nbsp;ممارسة الرياضة بحاجة إلى تعديل. &nbsp;فاستشر طبيبك.<br />في حالة الارتفاع الشديد في نسبة السكر في الدم<br />قد يرتفع معدل السكر في الدم بدرجة كبيرة ارتفاع السكر في الدم. وقد يحدث هذا في الحالات التالية:<br />&bull; عند تناول كمية قليلة جدًّا من نوفونورم&reg;<br />&bull; إذا كنت مصاباً بعدوى أو حمى<br />&bull; عند تناول الطعام بشكل أكثر من المعتاد<br />&bull; عند ممارسة الرياضة بشكل أقل من المعتاد<br />تظهر أعراض ارتفاع سكر الدم الشديد بشكل تدريجي. وهي تتضمن: ارتفاع معدلات التبول؛ الشعور بالعطش؛ جفاف البشرة والفم.&nbsp;&nbsp;فقد تكون كمية دواء نوفونورم &reg;&nbsp;أو الطعام أو &nbsp;ممارسة الرياضة بحاجة إلى تعديل. &nbsp;فاستشر طبيبك.<br />&reg; الأدوية الأخرى و نوفونورم<br />استشر طبيبك إذا كنت تتناول أي أدوية أخرى حاليًا أو تناولتها مؤخرًا أو قد تتناولها في المستقبل.<br />يمكنك أن تتناول نوفونورم&reg; مع دواء ميتفورمين أو ثيازوليدينديون، أو غيرهما من أدوية علاج السكري، إذا وصفها الطبيب لك.<br />وإذا كنت تتناول دواء جيمفيبروزيل يستخدم في خفض مستويات الدهون المرتفعة في الدم، فلا ينبغي. لك أن تتناول دواء نوفونورم&reg;<br />إذا تناولت قد تتغير استجابة جسمك لدواء نوفونورم&reg; معه أدوية أخرى، خاصة الأدوية التالية:<br />تستخدم MAOI&bull; مثبطات أوكسيداز مونوامين في علاج الاكتئاب<br />&bull; مثبطات بيتا تستخدم في علاج ارتفاع ضغط الدم أو أمراض القلب<br />&bull; مثبطات الأنزيم المحوّل للأنجيوتنسين ستخدم في علاج أمراض القلب<br />&bull; السالسيلات مثل الأسبرين<br />&bull; أوكتريوتايد يستخدم لعلاج السرطان<br />&bull; العقاقير المضادة للالتهابات غير الستيرويدية<br />نوع من مسكنات الألم NSAID<br />&bull; الستيرويدات الستيرويدات الابتنائية<br />والكورتيكوستيرويدات - تستخدم في علاج الأنيميا أو الالتهابات<br />&bull; وسائل منع الحمل الفموية حبوب منع الحمل<br />&bull; ثيازيدات مدرات البول أو &lsquo;الحبوب المائية&lsquo;<br />&bull; دانازول يستخدم في علاج خراج الثدي والتهاب بطانة الرحم<br />&bull; أدوية الغدة الدرقية تستخدم في علاج انخفاض مستويات هرمون الغدة الدرقية<br />&bull; محاكيات الودِّي تستخدم في علاج الربو<br />&bull; كلاريثروميسين، ترايميثوبريم، ريفامبيسين<br />مضادات حيوية<br />&bull; ايتراكونازول، كيتوكونازول مضادة للفطريات<br />&bull; جيمفيبروزيل يستخدم في علاج ارتفاع نسبة<br />الدهون في الدم<br />&bull; سيكلوسبورين يستخدم في قمع جهاز المناعة<br />&bull; ديفيراسيروكس يستخدم في تقليل الحديد الزائد المزمن<br />&bull; كلوبيدوجريل يمنع تجلط الدم<br />&bull; فينيتوين، كاربامازبين، فينوباربيتال تُستخدم في علاج الصرع<br />&bull; عشبة القديس يوحنا - أعشاب طبية -<br />تناول نوفونورم&reg;&nbsp;مع الكحول<br />قد يغير الكحول من فعالية نوفونورم&reg;&nbsp;في خفض مستوى السكر في الدم. ينبغي ملاحظة أعراض نقص سكر الدم.</p><p><br />الحمل والرضاعة الطبيعية<br />إذا كنت حاملاً أو مرضعاً، أو تعتقدين أنك قد تكونين حاملاً أو تخططين للحمل مستقبلاً، فاستشيري طبيبك واطلبي منه النصيحة قبل تناول الدواء. فلا ينبغي&nbsp; استخدام دواء نوفونورم&reg; في حالة الحمل أو التخطيط للحمل.<br />ينبغي عدم استخدام نوفونورم&reg;&nbsp;في حالة الرضاعة الطبيعية.</p><p>القيادة واستعمال الآلات<br />قد تتأثر قدرتك على القيادة أو استخدام الآلات إذا كنت ممن يعانون انخفاض السكر في الدم أو ارتفاعه. فخذ بعين الاعتبار أنك قد تعرض نفسك أو الآخرين للخطر. من فضلك اسأل طبيبك عما إذا كان بإمكانك<br />قيادة المركبات أم لا في الحالات التالية:<br />&bull; الإصابة بحالة نقص سكر الدم بصفة متكررة<br />&bull; حدوث أعراض طفيفة لنقص سكر الدم أو عدم<br />حدوثها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>التزم دائماً بإرشادات الطبيب بدقة عند تناول هذا الدواء. وارجع إلى طبيبك إذا ساورك شك بشأن استخدام الدواء.<br />وسوف يحدد لك الطبيب الجرعة المناسبة لك.<br />&bull; الجرعة الأولى المعتادة هي 0.5 ملجم قبل كل وجبة رئيسية. ابتلع الأقراص مع كوب من الماء قبل كل وجبة رئيسية مباشرة أو قبلها ب 30 دقيقة.<br />&bull; قد يتم تعديل الجرعة بواسطة الطبيب بزيادة تصل إلى 4 ملجم تؤخذ قبل كل وجبة رئيسية مباشرة أو قبلها ب 30 دقيقة بحد أقصى. الجرعة القصوى اليومية الموصى بها هي 16 ملجم. بجرعة أكبر مما ينصح &reg; ينبغي عدم تناول نوفونورم به الطبيب.<br />ما يجب فعله عند تناول جرعة زائدة من نوفونورم&reg;</p><p>في حالة تناول جرعة كبيرة جداً من الأقراص، فقد ينخفض مستوى سكر الدم بدرجة كبيرة جداً مما يؤدي إلى حالة نقص سكر الدم. من فضلك راجع قسم في حالة الإصابة بنقص سكر الدم لمعرفة معنى حالة<br />نقص سكر الدم وكيفية علاجها.<br />ما يجب فعله في حالة نسيان تناول نوفونورم&reg;<br />إذا نسيت تناول جرعة، فتناول الجرعة التالية كالمعتاد - لا تضاعف الجرعة.<br />ماذا يحدث في حالة التوقف عن تناول نوفونورم&reg;<br />يرجى العلم بأن التأثير المنشود لايتحقق في حالة&nbsp;التوقف عن تناول نوفونورم&reg; قد تسوء حالة داء السكري لديك. إذا كان من الضروري إجراء أي تغيير<br />في العلاج، فينبغي استشارة الطبيب أولاً.<br />إذا كانت لديك أي أسئلة أخرى بشأن استخدام&nbsp;نوفونورم&reg; فينبغي استشارة الطبيب أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>4. الآثار الجانبية المحتملة<br />مثل كل الأدوية، قد يسبب نوفونورم&reg;&nbsp;آثارًا جانبية،<br />وإن كانت لاتحدث في جميع الأشخاص الذين يستخدمونه.<br />نقص سكر الدم<br />أهم الآثار الجانبية لهذا الدواء هو نقص سكر الدم والذي قد يؤثر على 1 من بين كل 10 مرضى راجع قسم في حالة الإصابة بنقص سكر الدم. وعادة ما<br />تحدث ردود فعل نقص سكر الدم بنسب خفيفة/ متوسطة لكنها أحياناً تتطور إلى حدوث غيبوبة أو الإغماء بسبب نقص سكر الدم . فإذا حدث ذلك، ينبغي استشارة الطبيب على الفور.<br />الحساسية<br />الحساسية أثر جانبي نادر جدًا يؤثر على ما يصل إلى شخص واحد من بين كل 10000 مريض&nbsp;أعراض مثل التورم أو صعوبة التنفس أو سرعة نبضات القلب أو الشعور بالدوار أو التعرق قد تكون هذه أعراض رد فعل تحسسي. ينبغي استشارة الطبيب على الفور.<br />آثار جانبية أخرى<br />آثار جانبية شائعة تؤثر على ما يصل إلى مريض واحد من بين كل 10 مرضى<br />&bull; آلام المعدة<br />&bull; إسهال.<br />آثار جانبية نادرة تؤثر على ما يصل إلى مريض واحد من بين كل 1000 مريض<br />&bull; متلازمة الشريان التاجي الحادة لكنها قد لا تكون ناتجة عن تناول الدواء.<br />آثار جانبية نادرة جدًا تؤثر على ما يصل إلى مريض واحد من بين كل 10000 مريض<br />&bull; القيء<br />&bull; الإمساك<br />&bull; تشوش الرؤية<br />&bull; مشكلات حادة في الكبد، اضطراب وظائف الكبد<br />مثل زيادة إنزيمات الكبد في الدم.</p><p>آثار جانبية غير معروفة مدى التكرار<br />&bull; فرط الحساسية مثل الطفح الجلدي، حكة جلدية،<br />احمرار الجلد، تورم الجلد<br />&bull; الشعور بالإعياء الغثيان.<br />إذا أُصبت بأي آثار جانبية، فاستشر الطبيب أو الصيدلي. وهذا يشمل أي آثار جانبية غير مدرجة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احتفظ بنوفونورم&reg; بعيدا عن متناول الأطفال ونطاق رؤيتهم.</p><p>لا تستخدم الدواء بعد تاريخ انتهاء صلاحيته الموضح على العبوة وشرائط التعبئة بعد &lsquo;الانتهاء&rsquo;. يشير تاريخ انتهاء الصلاحية إلى التاريخ الأخير من ذلك الشهر. خزنه في عبوته الأصلية في درجة حرارة أقل من ٣٠<br />درجة مئوية كي تحفظه من الرطوبة.</p><p>ينبغي عدم التخلص من الأدوية في أحواض الصرف أو في سلة المهملات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعُد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي مادة الريباجلينايد.<br />المكونات الأخرى: سيليلوز دقيق البللورات (460E)<br />فوسفات هيدروجين الكالسيوم لا مائي، نشاء الذرة، بوتاسيوم بولاكريلين، بوفيدون (بوليفيدون)، جليسرول%85 ، ستيرات مغنيسيوم، ميجلومين، بولوكزامر،<br />أكسيد الحديد الأصفر (172E)&nbsp; فقط في الأقراص تركيز 1 ملجم فقط وأكسيد الحديد الأحمر&nbsp; (172E)&nbsp; فقط في الأقراص تركيز 2 ملجم فقط.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص نوفونورم&reg;&nbsp;مستديرة ومحدبة ومنقوش عليها&nbsp; شعارشركة نوفو نوردِسك الثور أبيس&nbsp;الأقراص التي تركيزها 0.5 ملجم بيضاء اللون، والأقراص التي تركيزها 1 ملجم صفراء اللون، أما الأقراص التي تركيزها 2 ملجم لونها خوخي .</p><p>شرائط التعبئة متوفرة بأحجام مختلفة. كل عبوة تحتوي على 30 قرصاً أو 90 قرصاً أو 120 قرصًا.<br />قد لا يتم تسويق العبوات بكل الأحجام.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>نوفو نوردِسك ايه اس<br />نوفو اليه<br />دي كيه- 2880 باجزفارد، الدنمارك</p><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">المركز الوطني للتيقظ الدوائي (NPC):</p><p dir="RTL">فاكس: +966-11-205-7662</p><p dir="RTL">مركز اتصالات الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p>الموقع الإلكتروني:</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            اكتوبر - 2022
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NovoNorm 1 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 1 mg of repaglinide. For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet

Repaglinide tablets are white, round and convex and engraved with Novo Nordisk logo (Apis bull).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. Repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone.</p><p>&nbsp;</p><p>Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Repaglinide is given preprandially and is titrated individually to optimise glycaemic control. In addition to the usual self-monitoring by the patient of blood and/or urinary glucose, the patient&rsquo;s blood glucose must be monitored periodically by the physician to determine the minimum effective dose for the patient. Glycosylated haemoglobin levels are also of value in monitoring the patient&rsquo;s response to therapy. Periodic monitoring is necessary to detect inadequate lowering of blood glucose at the recommended maximum dose level (i.e. primary failure) and to detect loss of adequate blood glucose-lowering response after an initial period of effectiveness (i.e. secondary failure).</p><p>&nbsp;</p><p>Short-term administration of repaglinide may be sufficient during periods of transient loss of control in type 2 diabetic patients usually controlled well on diet.</p><p><u>Initial dose</u></p><p>The dosage should be determined by the physician, according to the patient&rsquo;s requirements.</p><p>The recommended starting dose is 0.5 mg. One to two weeks should elapse between titration steps (as determined by blood glucose response).</p><p>If patients are transferred from another oral hypoglycaemic medicinal product, the recommended starting dose is 1 mg.</p><p><u>Maintenance</u></p><p>The recommended maximum single dose is 4 mg taken with main meals. The total maximum daily dose should not exceed 16 mg.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>No clinical studies have been conducted in patients &gt;75 years of age.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Repaglinide is not affected by renal disorders (see section 5.2).</p><p>Eight percent of one dose of repaglinide is excreted through the kidneys and total plasma clearance of the product is decreased in patients with renal impairment. As insulin sensitivity is increased in diabetic patients with renal impairment, caution is advised when titrating these patients.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No clinical studies have been conducted in patients with hepatic insufficiency.</p><p>&nbsp;</p><p><em>Debilitated or malnourished patients</em></p><p>In debilitated or malnourished patients the initial and maintenance dosage should be conservative and careful dose titration is required to avoid hypoglycaemic reactions.</p><p>&nbsp;</p><p><em>Patients receiving other oral hypoglycaemic medicinal products</em></p><p>Patients can be transferred directly from other oral hypoglycaemic medicinal products to repaglinide. However, no exact dosage relationship exists between repaglinide and the other oral hypoglycaemic medicinal products. The recommended maximum starting dose of patients transferred to repaglinide is 1 mg given before main meals.</p><p>&nbsp;</p><p>Repaglinide can be given in combination with metformin, when the blood glucose is insufficiently controlled with metformin alone. In this case, the dosage of metformin should be maintained and repaglinide administered concomitantly. The starting dose of repaglinide is 0.5 mg, taken before main meals; titration is according to blood glucose response as for monotherapy.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>The safety and efficacy of repaglinide in children below 18 years have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Repaglinide should be taken before main meals (i.e. preprandially).</p><p>&nbsp;</p><p>Doses are usually taken within 15 minutes of the meal but time may vary from immediately preceding the meal to as long as 30 minutes before the meal (i.e. preprandially 2, 3, or 4 meals a day). Patients who skip a meal (or add an extra meal) should be instructed to skip (or add) a dose for that meal.</p><p>&nbsp;</p><p>In the case of concomitant use with other active substances refer to sections 4.4 and 4.5 to assess the dosage.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to repaglinide or to any of the excipients listed in section 6.1.
•	Diabetes mellitus type 1, C-peptide negative.
•	Diabetic ketoacidosis, with or without coma.
•	Severe hepatic function disorder.
•	Concomitant use of gemfibrozil (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General</u></p><p>Repaglinide should only be prescribed if poor blood glucose control and symptoms of diabetes persist despite adequate attempts at dieting, exercise and weight reduction.</p><p>&nbsp;</p><p>When a patient stabilised on any oral hypoglycaemic medicinal product is exposed to stress such as fever, trauma, infection or surgery, a loss of glycaemic control may occur. At such times, it may be necessary to discontinue repaglinide and treat with insulin on a temporary basis.</p><p>&nbsp;</p><p><u>Hypoglycaemia</u></p><p>Repaglinide, like other insulin secretagogues, is capable of producing hypoglycaemia.</p><p>&nbsp;</p><p><u>Combination with insulin secretagogues</u></p><p>The blood glucose-lowering effect of oral hypoglycaemic medicinal products decreases in many patients over time. This may be due to progression of the severity of the diabetes or to diminished responsiveness to the medicinal product. This phenomenon is known as secondary failure, to distinguish it from primary failure, where the medicinal product is ineffective in an individual patient when first given. Adjustment of dose and adherence to diet and exercise should be assessed before classifying a patient as a secondary failure.</p><p>&nbsp;</p><p>Repaglinide acts through a distinct binding site with a short action on the &beta;-cells. Use of repaglinide in case of secondary failure to insulin secretagogues has not been investigated in clinical trials.</p><p>Trials investigating the combination with other insulin secretagogues have not been performed.</p><p>&nbsp;</p><p><u>Combination with Neutral Protamine Hagedorn (NPH) insulin or thiazolidinediones</u></p><p>Trials of combination therapy with NPH insulin or thiazolidinediones have been performed. However, the benefit risk profile remains to be established when comparing to other combination therapies.</p><p>&nbsp;</p><p><u>Combination with metformin</u></p><p>Combination treatment with metformin is associated with an increased risk of hypoglycaemia.</p><p>&nbsp;</p><p><u>Acute coronary syndrome</u></p><p>The use of repaglinide might be associated with an increased incidence of acute coronary syndrome (e.g. myocardial infarction), see sections 4.8 and 5.1.</p><p>&nbsp;</p><p><u>Concomitant use</u></p><p>Repaglinide should be used with caution or be avoided in patients receiving medicinal products which influence repaglinide metabolism (see section 4.5). If concomitant use is necessary, careful&nbsp; monitoring of blood glucose and close clinical monitoring should be performed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A number of medicinal products are known to influence repaglinide metabolism. Possible interactions should therefore be taken into account by the physician:</p><p>&nbsp;</p><p><em>In vitro </em>data indicate that repaglinide is metabolised predominantly by CYP2C8, but also by CYP3A4. Clinical data in healthy volunteers support CYP2C8 as being the most important enzyme involved in repaglinide metabolism with CYP3A4 playing a minor role, but the relative contribution of CYP3A4 can be increased if CYP2C8 is inhibited. Consequently metabolism, and by that clearance of&nbsp;repaglinide, may be altered by substances which influence these cytochrome P-450 enzymes via inhibition or induction. Special care should be taken when inhibitors of both CYP2C8 and 3A4 are co-administered simultaneously with repaglinide.</p><p>&nbsp;</p><p>Based on <em>in vitro </em>data, repaglinide appears to be a substrate for active hepatic uptake (organic anion transporting protein OATP1B1). Substances that inhibit OATP1B1 may likewise have the potential to increase plasma concentrations of repaglinide, as has been shown for ciclosporin (see below).</p><p>&nbsp;</p><p>The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide: Gemfibrozil, clarithromycin, itraconazole, ketokonazole, trimethoprim, ciclosporin, deferasirox, clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs, octreotide, alcohol, and anabolic steroids.</p><p>&nbsp;</p><p>Co-administration of gemfibrozil (600 mg twice daily), an inhibitor of CYP2C8, and repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC 8.1-fold and C<sub>max</sub> 2.4-fold in healthy volunteers. Half-life was prolonged from 1.3 hr to 3.7 hr, resulting in possibly enhanced and prolonged blood glucose-lowering effect of repaglinide, and plasma repaglinide concentration at 7 hr was increased 28.6-fold by gemfibrozil. The concomitant use of gemfibrozil and repaglinide is contraindicated (see section 4.3).</p><p>&nbsp;</p><p>Co-administration of trimethoprim (160 mg twice daily), a moderate CYP2C8 inhibitor, and repaglinide (a single dose of 0.25 mg) increased the repaglinide AUC, C<sub>max</sub> and t<sub>&frac12;</sub> (1.6-fold, 1.4-fold and 1.2-fold respectively) with no statistically significant effects on the blood glucose levels. This lack of pharmacodynamic effect was observed with a sub-therapeutic dose of repaglinide. Since the safety profile of this combination has not been established with dosages higher than 0.25 mg for repaglinide and 320 mg for trimethoprim, the concomitant use of trimethoprim with repaglinide should be avoided. If concomitant use is necessary, careful monitoring of blood glucose and close clinical monitoring should be performed (see section 4.4).</p><p>&nbsp;</p><p>Rifampicin, a potent inducer of CYP3A4, but also CYP2C8, acts both as an inducer and inhibitor of the metabolism of repaglinide. Seven days pre-treatment with rifampicin (600 mg), followed by co- administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC (effect of a combined induction and inhibition). When repaglinide was given 24 hours after the last rifampicin dose, an 80% reduction of the repaglinide AUC was observed (effect of induction alone). Concomitant use of rifampicin and repaglinide might therefore induce a need for repaglinide dose adjustment which should be based on carefully monitored blood glucose concentrations at both initiation of rifampicin treatment (acute inhibition), following dosing (mixed inhibition and induction), withdrawal (induction alone) and up to approximately two weeks after withdrawal of rifampicin where the inductive effect of rifampicin is no longer present. It cannot be excluded that other inducers, e.g. phenytoin, carbamazepine, phenobarbital, St John&rsquo;s wort, may have a similar effect.</p><p>&nbsp;</p><p>The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg ketoconazole increased the repaglinide (AUC and C<sub>max</sub>) by 1.2-fold with profiles of blood glucose concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose level in healthy volunteers was observed. In an interaction study in healthy volunteers, co- administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly increased the repaglinide (AUC) by 1.4-fold and C<sub>max</sub> by 1.7-fold and increased the mean incremental AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism of this interaction is not clear.</p><p>&nbsp;</p><p>In a study conducted in healthy volunteers, the concomitant administration of repaglinide (a single dose of 0.25 mg) and ciclosporin (repeated dose at 100 mg) increased repaglinide AUC and C<sub>max</sub> about 2.5-fold and 1.8-fold respectively. Since the interaction has not been established with dosages higher than 0.25 mg for repaglinide, the concomitant use of ciclosporin with repaglinide should be avoided. If the combination appears necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4).</p><p>&nbsp;</p><p>In an interaction study with healthy volunteers, co-administration of deferasirox (30 mg/kg/day, 4&nbsp; days), a moderate inhibitor of CYP2C8 and CYP3A4, and repaglinide (single dose, 0.5 mg) resulted in an increase in repaglinide systemic exposure (AUC) to 2.3-fold (90% CI [2.03-2.63]) of control, a 1.6-fold (90% CI [1.42-1.84]) increase in C<sub>max</sub>, and a small, significant decrease in blood glucose values. Since the interaction has not been established with dosages higher than 0.5 mg for repaglinide, the concomitant use of deferasirox with repaglinide should be avoided. If the combination appears necessary, careful clinical and blood glucose monitoring should be performed (see section 4.4).</p><p>&nbsp;</p><p>In an interaction study with healthy volunteers, co-administration of <em>clopidogrel </em>(300 mg loading dose), a CYP2C8 inhibitor, increased repaglinide exposure (AUC0&ndash;&infin;) 5.1-fold and continued administration (75 mg daily dose) increased repaglinide exposure (AUC0&ndash;&infin;) 3.9-fold. A small, significant decrease in blood glucose values was observed. Since the safety profile of the co-treatment has not been established in these patients, the concomitant use of clopidogrel and repaglinide should be avoided. If concomitant use is necessary, careful monitoring of blood glucose and close clinical monitoring should be performed (see section 4.4).</p><p>&nbsp;</p><p>&beta;-blocking medicinal products may mask the symptoms of hypoglycaemia.</p><p>&nbsp;</p><p>Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4 substrates, did not significantly alter the pharmacokinetic parameters of repaglinide.</p><p>&nbsp;</p><p>Repaglinide had no clinically relevant effect on the pharmacokinetic properties of digoxin, theophylline or warfarin at steady state, when administered to healthy volunteers. Dosage adjustment of these compounds when co-administered with repaglinide is therefore not necessary.</p><p>&nbsp;</p><p>The following substances may reduce the hypoglycaemic effect of repaglinide:</p><p>Oral contraceptives, rifampicin, barbiturates, carbamazepine, thiazides, corticosteroids, danazol, thyroid hormones and sympathomimetics.</p><p>&nbsp;</p><p>When these medications are administered to or withdrawn from a patient receiving repaglinide, the patient should be observed closely for changes in glycaemic control.</p><p>&nbsp;</p><p>When repaglinide is used together with other medicinal products that are mainly secreted by the bile, like repaglinide, any potential interaction should be considered.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>No interaction studies have been performed in children and adolescents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no studies of repaglinide in pregnant women. Repaglinide should be avoided during pregnancy.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>There are no studies in breast-feeding women. Repaglinide should not be used in breast-feeding women.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>Data from animal studies investigating effects on embryofetal and offspring development as well as excretion in milk is described in section 5.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NovoNorm has no direct influence on the ability to drive and use machines but may cause hypoglycaemia.</p><p>&nbsp;</p><p>Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warning signs of hypoglycaemia or have frequent episodes of hypoglycaemia. The advisability of driving should be considered in these circumstances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequently reported adverse reactions are changes in blood glucose levels, i.e. hypoglycaemia. The occurrence of such reactions depends on individual factors, such as dietary habits, dosage, exercise and stress.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>Based on the experience with repaglinide and with other hypoglycaemic medicinal products the following adverse reactions have been seen: Frequencies are defined as: common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000) and not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p>Immune system disorders</p></td><td><p>Allergic reactions*</p></td><td><p>Very rare</p></td></tr><tr><td rowspan="2"><p>Metabolism and nutrition disorders</p></td><td><p>Hypoglycaemia</p></td><td><p>Common</p></td></tr><tr><td><p>Hypoglycaemic coma and hypoglycaemic unconsciousness</p></td><td><p>Not known</p></td></tr><tr><td><p>Eye disorders</p></td><td><p>Refraction disorder*</p></td><td><p>Very rare</p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>Cardiovascular disease</p></td><td><p>Rare</p></td></tr><tr><td rowspan="3"><p>Gastrointestinal disorders</p></td><td><p>Abdominal pain, diarrhoea</p></td><td><p>Common</p></td></tr><tr><td><p>Vomiting, constipation</p></td><td><p>Very rare</p></td></tr><tr><td><p>Nausea</p></td><td><p>Not known</p></td></tr><tr><td><p>Hepatobiliary disorders</p></td><td><p>Abnormal hepatic function, increased liver enzymes*</p></td><td><p>Very rare</p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Hypersensitivity*</p></td><td><p>Not known</p></td></tr></tbody></table><p>* see section Description of selected adverse reactions below</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Allergic reactions</em></p><p>Generalised hypersensitivity reactions (e.g. anaphylactic reaction), or immunological reactions such as vasculitis.</p><p>&nbsp;</p><p><em>Refraction disorders</em></p><p>Changes in blood glucose levels have been known to result in transient visual disturbances, especially at the commencement of treatment. Such disturbances have only been reported in very few cases after initiation of repaglinide treatment. No such cases have led to discontinuation of repaglinide treatment in clinical trials.</p><p>&nbsp;</p><p><em>Abnormal hepatic function, increased liver enzymes</em></p><p>Isolated cases of increased liver enzymes have been reported during treatment with repaglinide. Most cases were mild and transient, and very few patients discontinued treatment due to increased liver enzymes. In very rare cases, severe hepatic dysfunction has been reported.</p><p>&nbsp;</p><p><em>Hypersensitivity</em></p><p>Hypersensitivity reactions of the skin may occur as erythema, itching, rashes and urticaria. There is no reason to suspect cross-allergenicity with sulphonylurea due to the difference in chemical structure.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:100%"><tbody><tr><td>The National Pharmacovigilance Centre (NPC):<br />Fax: +966-11-205-7662<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Repaglinide has been given with weekly escalating doses from 4 - 20 mg four times daily in a 6 week period. No safety concerns were raised. As hypoglycaemia in this study was avoided through increased calorie intake, a relative overdose may result in an exaggerated glucose-lowering effect with development of hypoglycaemic symptoms (dizziness, sweating, tremor, headache etc.). Should these symptoms occur, adequate action should be taken to correct the low blood glucose (oral carbohydrates). More severe hypoglycaemia with seizure, loss of consciousness or coma should be treated with intravenous glucose.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmaco-therapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins, ATC code: A10BX02</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Repaglinide is a short-acting oral secretagogue. Repaglinide lowers the blood glucose levels acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning &beta;-cells in the pancreatic islets.</p><p>Repaglinide closes ATP-dependent potassium channels in the &beta;-cell membrane via a target protein different from other secretagogues. This depolarises the &beta;-cell and leads to an opening of the calcium channels. The resulting increased calcium influx induces insulin secretion from the &beta;-cell.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>In type 2 diabetic patients, the insulinotropic response to a meal occurred within 30 minutes after an oral dose of repaglinide. This resulted in a blood glucose-lowering effect throughout the meal period.</p><p>&nbsp;</p><p>The elevated insulin levels did not persist beyond the time of the meal challenge. Plasma repaglinide levels decreased rapidly, and low concentrations were seen in the plasma of type 2 diabetic patients&nbsp; 4 hours post-administration.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>A dose-dependent decrease in blood glucose was demonstrated in type 2 diabetic patients when administered in doses from 0.5 to 4 mg repaglinide.</p><p>Clinical study results have shown that repaglinide is optimally dosed in relation to main meals (preprandial dosing).</p><p>Doses are usually taken within 15 minutes of the meal, but the time may vary from immediately preceding the meal to as long as 30 minutes before the meal.</p><p>&nbsp;</p><p>One epidemiological study suggested an increased risk of acute coronary syndrome in repaglinide treated patients as compared to sulfonylurea treated patients (see sections 4.4 and 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Repaglinide is rapidly absorbed from the gastrointestinal tract, which leads to a rapid increase in the plasma concentration of the active substance. The peak plasma level occurs within one hour post administration. After reaching a maximum, the plasma level decreases rapidly.</p><p>Repaglinide pharmacokinetics are characterised by a mean absolute bioavailability of 63% (CV 11%).</p><p>&nbsp;</p><p>No clinically relevant differences were seen in the pharmacokinetics of repaglinide, when repaglinide was administered 0, 15 or 30 minutes before a meal or in fasting state.</p><p>&nbsp;</p><p>A high interindividual variability (60%) in repaglinide plasma concentrations has been detected in the clinical trials. Intraindividual variability is low to moderate (35%) and as repaglinide should be titrated against the clinical response, efficacy is not affected by interindividual variability.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Repaglinide pharmacokinetics are characterised by low volume of distribution, 30 L (consistent with distribution into intracellular fluid) and is highly bound to plasma proteins in humans (greater than 98%).</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Repaglinide is eliminated rapidly within 4 - 6 hours from the blood. The plasma elimination half-life is approximately one hour.</p><p>&nbsp;</p><p>Repaglinide is almost completely metabolised, and no metabolites with clinically relevant hypoglycaemic effect have been identified.</p><p>&nbsp;</p><p>Repaglinide metabolites are excreted primarily via the bile. A small fraction (less than 8%) of the administered dose appears in the urine, primarily as metabolites. Less than 1% of repaglinide is recovered in faeces.</p><p>&nbsp;</p><p><u>Special patient groups</u></p><p>&nbsp;</p><p>Repaglinide exposure is increased in patients with hepatic insufficiency and in the elderly type 2 diabetic patients. The AUC (SD) after 2 mg single dose exposure (4 mg in patients with hepatic insufficiency) was 31.4 ng/ml x hr (28.3) in healthy volunteers, 304.9 ng/ml x hr (228.0) in patients with hepatic insufficiency, and 117.9 ng/ml x hr (83.8) in the elderly type 2 diabetic patients.</p><p>&nbsp;</p><p>After a 5 day treatment of repaglinide (2 mg x 3/day) in patients with a severe impaired renal function (creatinine clearance: 20-39 ml/min.), the results showed a significant 2-fold increase of the exposure (AUC) and half-life (t<sub>1/2</sub>) as compared to patients with normal renal function.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>No data are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data revealed no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential.</p><p>&nbsp;</p><p>Repaglinide was shown not to be teratogenic in animal studies. Embryotoxicity, abnormal limb development in rat foetuses and new born pups, was observed in female rats exposed to high doses in the last stage of pregnancy and during the lactation period. Repaglinide was detected in the milk of animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Microcrystalline cellulose (E460)</p><p>Calcium hydrogen phosphate, anhydrous</p><p>Maize starch</p><p>Polacrilin potassium</p><p>Povidone (polyvidone)</p><p>Glycerol 85%</p><p>Magnesium stearate</p><p>Meglumine</p><p>Poloxamer</p><p>Iron oxide, yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                5 Years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in the original package in order to protect from moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The blister pack (aluminium/aluminium) contains 30, 90, 120 or 270 tablets, respectively. Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Novo Nordisk A/S 
Novo Allé
DK-2880 Bagsværd Denmark

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Oct/2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>